NovaBay Pharmaceuticals Selling Avenova Assets to Physician Recommended Nutraceuticals

Friday, 20 September 2024, 10:28

NovaBay Pharmaceuticals shares trade higher as the company announces a definitive agreement to sell its Avenova assets for $9.5 million. This strategic move is expected to bolster the company's financial standing and focus on core innovations. Investors should monitor the impact of this transaction on NovaBay's future growth.
Benzinga
NovaBay Pharmaceuticals Selling Avenova Assets to Physician Recommended Nutraceuticals

Strategic Sale of Avenova Assets

NovaBay Pharmaceuticals is witnessing an uptick in its share price following a major announcement. The firm has reached a definitive agreement to sell its Avenova assets to Physician Recommended Nutraceuticals for $9.5 million.

Impact on NovaBay's Financial Health

  • This agreement is part of a broader strategy to strengthen NovaBay's core operations.
  • The funds from this sale are expected to enhance the company's liquidity and funding for future projects.
  • Both parties are optimistic about this transaction, which marks a significant shift in NovaBay's focus.

Investors should stay tuned for future developments as this sale progresses, potentially leading to an uplift in market confidence.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most accurate and current medical news. Stay updated and deepen your understanding of medical advancements effortlessly.

Subscribe